

Andrejs Erglis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4310452/publications.pdf>

Version: 2024-02-01

171
papers

16,740
citations

41344

49
h-index

15266

126
g-index

174
all docs

174
docs citations

174
times ranked

13767
citing authors

#	ARTICLE	IF	CITATIONS
1	Five year clinical outcomes of the COBRA Polyzene F NanoCoated Coronary Stent System. Cardiovascular Revascularization Medicine, 2022, , .	0.8	2
2	What Is Hidden Behind Yellow Pixels: from Pathology to Intravascular Imaging of Atherosclerotic Plaque. Current Atherosclerosis Reports, 2022, 24, 97.	4.8	0
3	Risk factors associated with mortality in the infective endocarditis patients requiring cardiac surgery: a study based on Latvian population. Journal of Cardiovascular Surgery, 2022, , .	0.6	0
4	Impact of dual antiplatelet therapy duration on clinical outcome after coronary bifurcation stenting: results from the Euro Bifurcation Club registry. Panminerva Medica, 2022, , .	0.8	1
5	Comparative Analysis of the Most Important Cardiovascular Risk Factors Based on Cross-Sectional Studies in the Population of Latvia. Medicina (Lithuania), 2022, 58, 643.	2.0	0
6	Alirocumab and Cardiovascular Outcomes in Patients With Previous Myocardial Infarction: Prespecified Subanalysis From ODYSSEY OUTCOMES. Canadian Journal of Cardiology, 2022, 38, 1542-1549.	1.7	4
7	Coronary revascularization of patients with silent coronary ischemia may reduce the risk of myocardial infarction and cardiovascular death after carotid endarterectomy. Journal of Vascular Surgery, 2022, 76, 750-759.	1.1	6
8	Diagnosis and management of silent coronary ischemia in patients undergoing carotid endarterectomy. Journal of Vascular Surgery, 2021, 73, 533-541.	1.1	7
9	Clinical pre-test probability for obstructive coronary artery disease: insights from the European DISCHARGE pilot study. European Radiology, 2021, 31, 1471-1481.	4.5	10
10	Comparison of outcome between blood culture positive and negative infective endocarditis patients undergoing cardiac surgery. Journal of Cardiothoracic Surgery, 2021, 16, 147.	1.1	6
11	Reperfusion therapies and in-hospital outcomes for ST-elevation myocardial infarction in Europe: the ACVC-EAPCI EORP STEMI Registry of the European Society of Cardiology. European Heart Journal, 2021, 42, 4536-4549.	2.2	37
12	A multicentre, prospective, randomised controlled trial to assess the safety and effectiveness of cooling as an adjunctive therapy to percutaneous intervention in patients with acute myocardial infarction: the COOL AMI EU Pivotal Trial. EuroIntervention, 2021, 17, 466-473.	3.2	18
13	Two-year outcomes from the MitrA Valve Repair Clinical (MAVERIC) trial: a novel percutaneous treatment of functional mitral regurgitation. European Journal of Heart Failure, 2021, 23, 1775-1783.	7.1	7
14	Influenza Vaccination After Myocardial Infarction: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial. Circulation, 2021, 144, 1476-1484.	1.6	121
15	Pacemaker-Based Cardiac Neuromodulation Therapy in Patients With Hypertension: A Pilot Study. Journal of the American Heart Association, 2021, 10, e020492.	3.7	8
16	The Full Revasc (Ffr-guidance for complete non-culprit REVASCularization) Registry-based randomized clinical trial. American Heart Journal, 2021, 241, 92-100.	2.7	4
17	Transcatheter reshaping of the mitral annulus in patients with functional mitral regurgitation: one-year outcomes of the MAVERIC trial. EuroIntervention, 2021, 16, 1106-1113.	3.2	11
18	Plasma circulating microRNAs in patients with stable coronary artery disease - Impact of different cardiovascular risk profiles and glomerular filtration rates. Journal of Clinical and Translational Research, 2021, 7, 270-276.	0.3	0

#	ARTICLE	IF	CITATIONS
19	A case report of pulmonary vein isolation performed in a patient with polysplenia and interrupted inferior vena cava. European Heart Journal - Case Reports, 2021, 5, ytab480.	0.6	1
20	Five-Year Results of the Bioflow-III Registry: Real-World Experience with a Biodegradable Polymer Sirolimus-Eluting Stent. Cardiovascular Revascularization Medicine, 2020, 21, 63-69.	0.8	12
21	Percutaneous coronary angioplasty versus coronary artery bypass grafting in the treatment of unprotected left main stenosis: updated 5-year outcomes from the randomised, non-inferiority NOBLE trial. Lancet, The, 2020, 395, 191-199.	13.7	280
22	European Society of Cardiology: Cardiovascular Disease Statistics 2019. European Heart Journal, 2020, 41, 12-85.	2.2	690
23	Long-Term Performance of the COMBO Dual-Therapy Stent: Results from the REMEDEE Registry. Cardiovascular Revascularization Medicine, 2020, 21, 567-570.	0.8	3
24	Ischemic Myocardial Burden Subtended by Computed Tomographyâ€“Derived Fractional Flow Reserve (APPROACHFFRCT). JACC: Cardiovascular Imaging, 2020, 13, 2264-2267.	5.3	7
25	Pre-operative Diagnosis of Silent Coronary Ischaemia May Reduce Post-operative Death and Myocardial Infarction and Improve Survival of Patients Undergoing Lower Extremity Surgical Revascularisation. European Journal of Vascular and Endovascular Surgery, 2020, 60, 411-420.	1.5	11
26	Lower ST-elevation myocardial infarction incidence during COVID-19 epidemic in Northern Europe. Scandinavian Cardiovascular Journal, 2020, 54, 358-360.	1.2	8
27	Final fiveâ€“year results of the REMEDEE Registry: Realâ€“world experience with the dualâ€“therapy COMBO stent. Catheterization and Cardiovascular Interventions, 2020, 98, 503-510.	1.7	6
28	Health-related quality of life, angina type and coronary artery disease in patients with stable chest pain. Health and Quality of Life Outcomes, 2020, 18, 140.	2.4	14
29	Randomised comparison of provisional side branch stenting versus a two-stent strategy for treatment of true coronary bifurcation lesions involving a large side branch: the Nordic-Baltic Bifurcation Study IV. Open Heart, 2020, 7, e000947.	2.3	34
30	Intravascular ultrasound to guide left main stem intervention: a NOBLE trial substudy. EuroIntervention, 2020, 16, 201-209.	3.2	48
31	Second European Cardiac Resynchronisation Therapy Survey (Crt Survey II): Latvian Data Compared to Europe. Proceedings of the Latvian Academy of Sciences, 2020, 74, 358-365.	0.1	0
32	Exercise, Chronotropic and Inotropic Capacity in Athletes with Different Training Programmes. Proceedings of the Latvian Academy of Sciences, 2020, 74, 18-24.	0.1	0
33	Thirty Years of Epidemiological Studies of Cardiovascular Disease Risk Factors in Latvia: Why are they Needed?. Proceedings of the Latvian Academy of Sciences, 2020, 74, 299-307.	0.1	0
34	Circulating plasma microRNA-126, microRNA-145, and microRNA-155 and their association with atherosclerotic plaque characteristics. Journal of Clinical and Translational Research, 2020, 5, 60-67.	0.3	6
35	Comparison of Major Adverse Cardiac Events Between Instantaneous Wave-Free Ratio and Fractional Flow Reserveâ€“Guided Strategy in Patients With or Without Type 2 Diabetes. JAMA Cardiology, 2019, 4, 857.	6.1	25
36	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes and Endocrinology, the, 2019, 7, 618-628.	11.4	207

#	ARTICLE	IF	CITATIONS
37	Sex Differences in Instantaneous Wave-Free Ratio or Fractional Flow Reserveâ€“Guided Revascularization Strategy. JACC: Cardiovascular Interventions, 2019, 12, 2035-2046.	2.9	26
38	Identification of patients and plaques vulnerable to future coronary events with near-infrared spectroscopy intravascular ultrasound imaging: a prospective, cohort study. Lancet, The, 2019, 394, 1629-1637.	13.7	263
39	Lead-Related Infective Endocarditis in Latvia: A Single Centre Experience. Medicina (Lithuania), 2019, 55, 566.	2.0	2
40	Clinical Events After Deferral of LADâ€“Revascularization Following Physiologicalâ€“Coronaryâ€“Assessment. Journal of the American College of Cardiology, 2019, 73, 444-453.	2.8	35
41	Derivation and Validation of a Chronic Total Coronary Occlusion Intervention Procedural Success Score From the 20,000-Patient EuroCTO Registry. JACC: Cardiovascular Interventions, 2019, 12, 335-342.	2.9	99
42	Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial. European Heart Journal, 2019, 40, 2801-2809.	2.2	45
43	Prognostic Value and Risk Continuum of Noninvasive Fractional Flow Reserve Derived from Coronary CT Angiography. Radiology, 2019, 292, 343-351.	7.3	89
44	Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. European Journal of Preventive Cardiology, 2019, 26, 824-835.	1.8	558
45	Roadmap for cardiovascular education across the European Society of Cardiology: inspiring better knowledge and skills, now and for the future. European Heart Journal, 2019, 40, 1728-1738.	2.2	8
46	Threeâ€“year clinical outcomes after dualâ€“therapy COMBO stent placement: Insights from the REMEDEE registry. Catheterization and Cardiovascular Interventions, 2019, 94, 342-347.	1.7	8
47	New-generation drug-eluting stents for left main coronary artery disease according to the EXCEL trial enrollment criteria: Insights from the all-comers, international, multicenter DELTA-2 registry. International Journal of Cardiology, 2019, 280, 30-37.	1.7	4
48	Mid-term outcomes after percutaneous interventions in coronary bifurcations. International Journal of Cardiology, 2019, 283, 78-83.	1.7	33
49	Incidence of cardiovascular events in patients with stabilized coronary heart disease: the EUROASPIRE IV follow-up study. European Journal of Epidemiology, 2019, 34, 247-258.	5.7	22
50	Treatment of Knee Osteoarthritis with Bone Marrowâ€“Derived Mononuclear Cell Injection: 12-Month Follow-up. Cartilage, 2019, 10, 26-35.	2.7	25
51	Pepsinogen Test for the Evaluation of Precancerous Changes in Gastric Mucosa: a Population-Based Study. Journal of Gastrointestinal and Liver Diseases, 2019, 27, 11-17.	0.9	10
52	A randomized multicentre trial to compare revascularization with optimal medical therapy for the treatment of chronic total coronary occlusions. European Heart Journal, 2018, 39, 2484-2493.	2.2	380
53	New-Generation Drug-Eluting Stents forâ€“Left Main In-Stent Restenosis. JACC: Cardiovascular Interventions, 2018, 11, 2438-2440.	2.9	3
54	1-Year Clinical Outcomes of All-Comer Patients Treated With the Dual-Therapy COMBO Stent. JACC: Cardiovascular Interventions, 2018, 11, 1969-1978.	2.9	21

#	ARTICLE	IF	CITATIONS
55	Latvian registry of familial hypercholesterolemia: The first report of three-year results. <i>Atherosclerosis</i> , 2018, 277, 347-354.	0.8	11
56	Cost-effectiveness of optimized adherence to prevention guidelines in European patients with coronary heart disease: Results from the EUROASPIRE IV survey. <i>International Journal of Cardiology</i> , 2018, 272, 20-25.	1.7	24
57	Safety of the Deferral of Coronary Revascularization on the Basis of Instantaneous Wave-Free Ratio and Fractional Flow Reserve Measurements in Stable Coronary Artery Disease and Acute Coronary Syndromes. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 1437-1449.	2.9	111
58	Two-year clinical outcomes after implantation of an everolimus-eluting bioresorbable scaffold (Absorb) in stable angina and acute coronary syndrome patients. Single-centre real-life registry data. <i>Postępy W Kardiologii Interwencyjnej</i> , 2018, 14, 144-148.	0.2	1
59	Randomised comparison of a biodegradable polymer ultra-thin sirolimus-eluting stent versus a durable polymer everolimus-eluting stent in patients with de novo native coronary artery lesions: the meriT-V trial. <i>EuroIntervention</i> , 2018, 14, e1207-e1214.	3.2	14
60	Transcatheter Vs. Surgical Closure of Atrial Septal Defects in Adults. <i>Proceedings of the Latvian Academy of Sciences</i> , 2018, 72, 16-22.	0.1	0
61	Original paper: A new type of polyphenols-containing dietary supplement for correction of lipids and inflammatory markers in patients with coronary artery disease. <i>Seminars in Cardiovascular Medicine</i> , 2018, 24, 22-28.	0.3	0
62	9-Month Clinical and Angiographic Outcomes of the COBRA Polyzene-F NanoCoated Coronary Stent System. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 160-167.	2.9	35
63	Evaluation of clinical outcomes after C<sc>OMBO</sc> stent treatment in patients presenting with acute coronary syndrome. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 90, E31-E37.	1.7	13
64	Design and rationale for the Influenza vaccination After Myocardial Infarction (IAMI) trial. A registry-based randomized clinical trial. <i>American Heart Journal</i> , 2017, 189, 94-102.	2.7	39
65	New insight to estimate under-expansion after stent implantation on bifurcation lesions using optical coherence tomography. <i>International Journal of Cardiovascular Imaging</i> , 2017, 33, 1677-1684.	1.5	11
66	The comparison of knee osteoarthritis treatment with single-dose bone marrow-derived mononuclear cells vs. hyaluronic acid injections. <i>Medicina (Lithuania)</i> , 2017, 53, 101-108.	2.0	21
67	Use of the Instantaneous Wave-free Ratio or Fractional Flow Reserve in PCI. <i>New England Journal of Medicine</i> , 2017, 376, 1824-1834.	27.0	742
68	The SABRE Trial (Sirolimus Angioplasty Balloon for Coronary In-Stent Restenosis). <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 2029-2037.	2.9	43
69	Two-year clinical outcomes of patients treated with the dual-therapy stent in a 1000 patient all-comers registry. <i>Open Heart</i> , 2017, 4, e000634.	2.3	13
70	Intravascular ultrasound assessment of minimum lumen area and intimal hyperplasia in in-stent restenosis after drug-eluting or bare-metal stent implantation. The Nordic Intravascular Ultrasound Study (NIVUS). <i>Cardiovascular Revascularization Medicine</i> , 2017, 18, 577-582.	0.8	15
71	Treatment of Secondary Mitral Regurgitation in Chronic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2834-2835.	2.8	8
72	Computed tomography versus invasive coronary angiography: design and methods of the pragmatic randomised multicentre DISCHARGE trial. <i>European Radiology</i> , 2017, 27, 2957-2968.	4.5	33

#	ARTICLE	IF	CITATIONS
73	One year clinical outcomes in patients with insulin-treated diabetes mellitus and non-insulin-treated diabetes mellitus compared to non-diabetics after deployment of the bio-engineered COMBO stent. International Journal of Cardiology, 2017, 226, 60-64.	1.7	20
74	Evaluating the quality of implantation of percutaneous ventricular restoration device (Parachute®) by cardiac computed tomography. Catheterization and Cardiovascular Interventions, 2017, 89, E104-E111.	1.7	1
75	Pacemaker-Mediated Programmable Hypertension Control Therapy. Journal of the American Heart Association, 2017, 6, .	3.7	16
76	The DELTA 2 Registry. JACC: Cardiovascular Interventions, 2017, 10, 2401-2410.	2.9	41
77	European Society of Cardiology Heart Failure Long-Term Registry (<scp>ESCâ€HFâ€LT</scp>): 1â€year follow-up outcomes and differences across regions. European Journal of Heart Failure, 2016, 18, 613-625.	7.1	538
78	Carotid artery stenting outcomes in high-risk patients receiving best medical therapy: results from a single high-volume interventional cardiology practice. Cor Et Vasa, 2016, 58, e569-e575.	0.1	0
79	Coronary bifurcation lesions treated with simple or complex stenting: 5-year survival from patient-level pooled analysis of the Nordic Bifurcation Study and the British Bifurcation Coronary Study. European Heart Journal, 2016, 37, 1923-1928.	2.2	103
80	Computing Methods for Composite Clinical Endpoints in Unprotected Left Main Coronary Artery Revascularization. JACC: Cardiovascular Interventions, 2016, 9, 2280-2288.	2.9	26
81	Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis (NOBLE): a prospective, randomised, open-label, non-inferiority trial. Lancet, The, 2016, 388, 2743-2752.	13.7	620
82	Cardiac computed tomography assessment of the near term impact of percutaneous ventricular restoration therapy (parachute®) on mitral valve geometry. Catheterization and Cardiovascular Interventions, 2016, 88, E45-51.	1.7	2
83	1-Year Results of the REMEDEE Registry. JACC: Cardiovascular Interventions, 2016, 9, 1127-1134.	2.9	45
84	Pilot study of safety and efficacy of polyprenols in combination with coenzyme Q10 in patients with statin-induced myopathy. Medicina (Lithuania), 2016, 52, 171-179.	2.0	7
85	EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. European Journal of Preventive Cardiology, 2016, 23, 636-648.	1.8	772
86	Long-term clinical outcomes after percutaneous coronary intervention versus coronary artery bypass grafting for acute coronary syndrome from the DELTA registry: a multicentre registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment. EuroIntervention, 2016, 12, e623-e631.	3.2	17
87	Real-world experience with a novel biodegradable polymer sirolimus-eluting stent: twelve-month results of the BIOFLOW-III registry. EuroIntervention, 2016, 11, 1106-1110.	3.2	35
88	Additive diagnostic value of atherosclerotic plaque characteristics to non-invasive FFR for identification of lesions causing ischaemia: results from a prospective international multicentre trial. EuroIntervention, 2016, 12, 473-481.	3.2	24
89	Management of coronary artery disease patients in Latvia compared with practice in Central-Eastern Europe and globally: Analysis of the CLARIFY registry. Medicina (Lithuania), 2015, 51, 240-246.	2.0	6
90	Next-generation-sequencing-based identification of familial hypercholesterolemia-related mutations in subjects with increased LDL-C levels in a latvian population. BMC Medical Genetics, 2015, 16, 86.	2.1	21

#	ARTICLE	IF	CITATIONS
91	Prevalence estimation of celiac disease in the general adult population of Latvia using serology and HLA genotyping. United European Gastroenterology Journal, 2015, 3, 190-199.	3.8	11
92	Patients with coronary artery disease and diabetes need improved management: a report from the EUROASPIRE IV survey: a registry from the EuroObservational Research Programme of the European Society of Cardiology. Cardiovascular Diabetology, 2015, 14, 133.	6.8	101
93	Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure. Circulation, 2015, 131, 54-61.	1.6	552
94	A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure. European Heart Journal, 2015, 36, 434-439.	2.2	80
95	Atherosclerotic Plaque Characteristics by ACT Angiography Identify Coronary Lesions That Cause Ischemia. JACC: Cardiovascular Imaging, 2015, 8, 1-10.	5.3	241
96	In-vivo iMap IVUS comparison of in-stent neointima and native coronary atherosclerosis. Cardiovascular Revascularization Medicine, 2015, 16, 233-236.	0.8	0
97	Primary endpoint results of the OMEGA Study: One-year clinical outcomes after implantation of a novel platinum chromium bare metal stent. Cardiovascular Revascularization Medicine, 2015, 16, 65-69.	0.8	14
98	Evaluation Of Massive Parallel Sequencing As A Diagnostic Tool For Familial Hypercholesterolemia. Proceedings of the Latvian Academy of Sciences, 2015, 69, 1-7.	0.1	0
99	Treatment of Heart Failure With Associated Functional Mitral Regurgitation Using the ARTO System. JACC: Cardiovascular Interventions, 2015, 8, 1095-1104.	2.9	57
100	Percutaneous ventricular restoration (PVR) therapy using the Parachute device in 100 subjects with ischaemic dilated heart failure: one-year primary endpoint results of PARACHUTE III, a European trial. EuroIntervention, 2015, 11, 710-717.	3.2	31
101	Technical aspects of the culotte technique. EuroIntervention, 2015, 11, V99-V101.	3.2	6
102	The Arto transcatheter mitral valve repair system. EuroIntervention, 2015, 14, W47-W48.	3.2	9
103	Response to Letter Regarding Article, "Noninvasive Fractional Flow Reserve Derived From Computed Tomography Angiography for Coronary Lesions of Intermediate Stenosis Severity: Results From the DeFACTO Study": Circulation: Cardiovascular Imaging, 2014, 7, 571-571.	2.6	0
104	Insufficient control of heart rate in stable coronary artery disease patients in Latvia. Medicina (Lithuania), 2014, 50, 295-302.	2.0	3
105	Plaque and blood vulnerability in ST segment elevation myocardial infarction patients. Coronary Artery Disease, 2014, 25, 104-110.	0.7	0
106	Reperfusion therapy for ST elevation acute myocardial infarction 2010/2011: current status in 37 ESC countries. European Heart Journal, 2014, 35, 1957-1970.	2.2	275
107	Long-Term Outcomes of Percutaneous Coronary Interventions or Coronary Artery Bypass Grafting for Left Main Coronary Artery Disease in Octogenarians (from a Drug-Eluting stent for Left main) Tj ETQq1 1 0.784314 rgBT / Overlock	1.4	0
108	Long-Term Clinical Outcomes After Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting for Ostial/Midshaft Lesions in Unprotected Left Main Coronary Artery From the DELTA Registry. JACC: Cardiovascular Interventions, 2014, 7, 354-361.	2.9	45

#	ARTICLE	IF	CITATIONS
109	Comparison of Percutaneous Coronary Intervention (With Drug-Eluting Stents) Versus Coronary Artery Bypass Grafting in Women With Severe Narrowing of the Left Main Coronary Artery (from the Tj ETQq1 1 0,784314 rgBT /Ovele	1.6	14
110	A Novel Noninvasive Technology for Treatment Planning Using Virtual Coronary Stenting and Computed Tomography-Derived Computed Fractional Flow Reserve. JACC: Cardiovascular Interventions, 2014, 7, 72-78.	2.9	144
111	Diagnostic Performance of Noninvasive Fractional Flow Reserve Derived From Coronary Computed Tomography Angiography in Suspected Coronary Artery Disease. Journal of the American College of Cardiology, 2014, 63, 1145-1155.	2.8	1,240
112	Prevalence of dyslipidemia in statin-treated patients in the Baltic states (Estonia, Latvia, and Lithuania): Results of the Dyslipidemia International Study (DYSIS). Medicina (Lithuania), 2014, 50, 44-53.	2.0	6
113	Role of genetic factors on the effect of additional loading doses and two maintenance doses used to overcome clopidogrel hyporesponsiveness. Medicina (Lithuania), 2014, 50, 19-27.	2.0	3
114	Decrease in annual incidence of acute coronary syndrome and restructuring of coronary care in Latvia. Cor Et Vasa, 2014, 56, e325-e332.	0.1	2
115	Intravascular Ultrasound-based Imaging Modalities for Tissue Characterisation. Interventional Cardiology Review, 2014, 9, 151.	1.6	13
116	Use of intravascular imaging in managing coronary artery disease. World Journal of Cardiology, 2014, 6, 393.	1.5	23
117	Control of Resting Heart Rate and Other Risk Factors Over a Three-year Period in Outpatients with Stable Coronary Artery Disease in Latvia. Proceedings of the Latvian Academy of Sciences, 2014, 67, 457-465.	0.1	0
118	Long-Term Results After Simple Versus Complex Stenting of Coronary Artery Bifurcation Lesions. Journal of the American College of Cardiology, 2013, 62, 30-34.	2.8	168
119	Long-Term Clinical Outcomes After Percutaneous Coronary Intervention for Ostial/Mid-Shaft Lesions Versus Distal Bifurcation Lesions in Unprotected Left Main Coronary Artery. JACC: Cardiovascular Interventions, 2013, 6, 1242-1249.	2.9	75
120	Clinical Outcome After Crush Versus Culotte Stenting of Coronary Artery Bifurcation Lesions. JACC: Cardiovascular Interventions, 2013, 6, 1160-1165.	2.9	51
121	Analysis of Stroke Occurring in the SYNTAX Trial Comparing Coronary Artery Bypass Surgery and Percutaneous Coronary Intervention in the Treatment of Complex Coronary Artery Disease. JACC: Cardiovascular Interventions, 2013, 6, 344-354.	2.9	46
122	Intravascular ultrasound assessed incomplete stent apposition and stent fracture in stent thrombosis after bare metal versus drug-eluting stent treatment the Nordic Intravascular Ultrasound Study (NIVUS). International Journal of Cardiology, 2013, 168, 1010-1016.	1.7	27
123	iMap intravascular ultrasound evaluation of culprit and non-culprit lesions in patients with ST-elevation myocardial infarction. Cardiovascular Revascularization Medicine, 2013, 14, 71-75.	0.8	13
124	A prospective, randomized trial of intravascular-ultrasound guided compared to angiography guided stent implantation in complex coronary lesions: The AVIO trial. American Heart Journal, 2013, 165, 65-72.	2.7	212
125	Noninvasive Fractional Flow Reserve Derived From Computed Tomography Angiography for Coronary Lesions of Intermediate Stenosis Severity. Circulation: Cardiovascular Imaging, 2013, 6, 881-889.	2.6	218
126	Healthy Alternatives of the Mediterranean Diet in Latvia. Proceedings of the Latvian Academy of Sciences, 2013, 67, 315-319.	0.1	0

#	ARTICLE	IF	CITATIONS
127	Follow-up of the patients after stem cell transplantation for pediatric dilated cardiomyopathy. Pediatric Transplantation, 2013, 17, 266-270.	1.0	34
128	Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Long-Term Registry. European Journal of Heart Failure, 2013, 15, 1173-1184.	7.1	533
129	Projected Costs and Consequences of Computed Tomography-Determined Fractional Flow Reserve. Clinical Cardiology, 2013, 36, 743-748.	1.8	71
130	Coronary artery bypass graft versus percutaneous coronary intervention with drug-eluting stent implantation for diabetic patients with unprotected left main coronary artery disease: the D-DELTA registry. EuroIntervention, 2013, 9, 803-808.	3.2	2
131	Prevalence of Helicobacter pylori infection and atrophic gastritis in Latvia. European Journal of Gastroenterology and Hepatology, 2012, 24, 1410-1417.	1.6	41
132	Expert review document part 2: methodology, terminology and clinical applications of optical coherence tomography for the assessment of interventional procedures. European Heart Journal, 2012, 33, 2513-2520.	2.2	349
133	Diagnostic Accuracy of Fractional Flow Reserve From Anatomic CT Angiography. JAMA - Journal of the American Medical Association, 2012, 308, 1237.	7.4	956
134	Effect of image quality on diagnostic accuracy of noninvasive fractional flow reserve: Results from the prospective multicenter international DISCOVER-FLOW study. Journal of Cardiovascular Computed Tomography, 2012, 6, 191-199.	1.3	87
135	Drug-Eluting Stent for Left Main Coronary Artery Disease. JACC: Cardiovascular Interventions, 2012, 5, 718-727.	2.9	121
136	Noninvasive Diagnosis of Ischemia-Causing Coronary Stenosis Using CT Angiography. JACC: Cardiovascular Imaging, 2012, 5, 1088-1096.	5.3	108
137	Usefulness of Noninvasive Fractional Flow Reserve Computed from Coronary Computed Tomographic Angiograms for Intermediate Stenoses Confirmed by Quantitative Coronary Angiography. American Journal of Cardiology, 2012, 110, 971-976.	1.6	85
138	A Population-Based Cross-Sectional Study of Cardiovascular Risk Factor in Latvia. Medicina (Lithuania), 2012, 48, 46.	2.0	6
139	Three-Dimensional Fourier-Domain Optical Coherence Tomography Imaging: Advantages and Future Development. Current Cardiovascular Imaging Reports, 2012, 5, 221-230.	0.6	5
140	Single nucleotide polymorphisms of the purinergic 1 receptor are not associated with myocardial infarction in a Latvian population. Molecular Biology Reports, 2012, 39, 1917-1925.	2.3	15
141	Side branch fractional flow reserve measurements after main vessel stenting: a Nordic-Baltic Bifurcation Study III substudy. EuroIntervention, 2012, 7, 1155-1161.	3.2	59
142	A population-based cross-sectional study of cardiovascular risk factor in Latvia. Medicina (Lithuania), 2012, 48, 310-6.	2.0	6
143	Diagnosis of Ischemia-Causing Coronary Stenoses by Noninvasive Fractional Flow Reserve Computed From Coronary Computed Tomographic Angiograms. Journal of the American College of Cardiology, 2011, 58, 1989-1997.	2.8	1,058
144	Simple or Complex Stenting for Bifurcation Coronary Lesions. Circulation: Cardiovascular Interventions, 2011, 4, 57-64.	3.9	152

#	ARTICLE	IF	CITATIONS
145	A common promoter variant of the gene encoding cyclooxygenase-1 (PTGS1) is related to decreased incidence of myocardial infarction in patients with coronary artery disease. Thrombosis Research, 2011, 127, 600-602.	1.7	2
146	Are Paclitaxel-Eluting Stents Better in Unprotected Left Main Coronary Artery Disease? Three-Year Clinical and Intravascular Imaging Results From a Randomized Study. Medicina (Lithuania), 2011, 47, 77.	2.0	2
147	Four-Year Follow-Up of TYPHOON (Trial to Assess the Use of the CYPHer Sirolimus-Eluting Coronary) Tj ETQq1 1 0.784314 rgBT /Over Interventions, 2011, 4, 14-23.	2.9	107
148	Extended follow-up safety and effectiveness of the Endeavor zotarolimus-eluting stent in real-world clinical practice: Two-year follow-up from the E-Flow Registry. Catheterization and Cardiovascular Interventions, 2011, 77, 993-1000.	1.7	13
149	Randomized Comparison of Final Kissing Balloon Dilatation Versus No Final Kissing Balloon Dilatation in Patients With Coronary Bifurcation Lesions Treated With Main Vessel Stenting. Circulation, 2011, 123, 79-86.	1.6	269
150	Intramyocardial administration of autologous bone marrow mononuclear cells in a critically ill child with dilated cardiomyopathy. Cardiology in the Young, 2011, 21, 110-112.	0.8	22
151	Lessons for the treatment of bifurcation lesions: from nowadays to the future. Interventional Cardiology, 2011, 3, 55-65.	0.0	1
152	Novel Baroreflex Activation Therapy in Resistant Hypertension. Journal of the American College of Cardiology, 2010, 56, 1254-1258.	2.8	321
153	Coronary guidewires. EuroIntervention, 2010, 6, 168-169.	3.2	15
154	Randomized Comparison of Coronary Bifurcation Stenting With the Crush Versus the Culotte Technique Using Sirolimus Eluting Stents. Circulation: Cardiovascular Interventions, 2009, 2, 27-34.	3.9	156
155	Relation of the Leu40Arg variant of glycoprotein IIIA to personal and family history of myocardial infarction. Proceedings of the Latvian Academy of Sciences, 2009, 63, 100-103.	0.1	0
156	Comparison of Intravascular Imaging and Quantitative Coronary Angiography to Evaluate Neointimal Proliferation after Complex Lesion Stenting. Proceedings of the Latvian Academy of Sciences, 2009, 63, 168-173.	0.1	0
157	Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis. BMJ: British Medical Journal, 2008, 337, a1331-a1331.	2.3	270
158	Safety in simple versus complex stenting of coronary artery bifurcation lesions. The Nordic Bifurcation Study 14-month follow-up results. EuroIntervention, 2008, 4, 229-233.	3.2	56
159	A Randomized Comparison of Paclitaxel-Eluting Stents Versus Bare-Metal Stents for Treatment of Unprotected Left Main Coronary Artery Stenosis. Journal of the American College of Cardiology, 2007, 50, 491-497.	2.8	103
160	Sirolimus-Eluting versus Uncoated Stents in Acute Myocardial Infarction. New England Journal of Medicine, 2006, 355, 1093-1104.	27.0	523
161	Intravascular Ultrasound Data and Results of Serum Biochemical Indices at the Time of Stenting and after Six Months in Patients with Coronary Artery Disease. Pteridines, 2006, 17, 95-99.	0.5	1
162	Randomized Study on Simple Versus Complex Stenting of Coronary Artery Bifurcation Lesions. Circulation, 2006, 114, 1955-1961.	1.6	666

#	ARTICLE	IF	CITATIONS
163	Inflammation, Homocysteine, Pyridoxal-5-phosphate and Lipids in Patients with Coronary Artery Disease before and Six Months after Coronary Angioplasty Followed by Stent Implantation. Pteridines, 2005, 16, 190-194.	0.5	1
164	Usefulness of Neopterin, C-reactive Protein, Homocysteine, Pyridoxal-5-phosphate, and Phospholipid Determination in Coronary Artery Disease. Pteridines, 2005, 16, 15-21.	0.5	4
165	Comparison of early and late results of a Carbofilm-coated stent versus a pure high-grade stainless steel stent (the Carbostent-Trial). American Journal of Cardiology, 2004, 93, 1351-1356.	1.6	32
166	Nitric Oxide Production and Arachidonic Acid Metabolism in Platelet Membranes of Coronary Heart Disease Patients with and without Diabetes. Medical Principles and Practice, 2003, 12, 10-16.	2.4	13
167	Heparin-Coated Stent Placement for the Treatment of Stenoses in Small Coronary Arteries of Symptomatic Patients. Circulation, 2003, 107, 1265-1270.	1.6	87
168	Prognostic Value of Tryptophan Load Test Followed by Serum Kynurenine Determination. It's Comparison With Pyridoxal-5-phosphate, Kynurenine, Homocysteine and Neopterin Amounts. Advances in Experimental Medicine and Biology, 2003, 527, 307-315.	1.6	7
169	Homocysteine, f Vitamins and Immune Activation in Coronary Heart Disease. Pteridines, 2003, 14, 82-87.	0.5	8
170	Comparing the sensitivity of pyridoxal-5-phosphate, homocysteine and neopterin in coronary heart disease. Pteridines, 2002, 13, 100-102.	0.5	1
171	Association between increased serum neopterin and homocysteine concentrations as well as pyridoxal-5-phosphate deficiency in patients with coronary heart disease. Pteridines, 2001, 12, 130-134.	0.5	7